Enterococcus faecalis and Enterococcus faecium have emerged as multi-resistant nosocomial pathogens in immunocompromised and critically ill patients. Multi-resistant strains have acquired virulence genes resulting in hospital-adapted clones. The following review summarizes several proteins and carbohydrate- or glycoconjugates that have been identified as putative virulence factors involved in the pathogenesis of enterococcal infections and may be used as targets for alternative therapies. Several studies describing the host immune response against enterococci are also summarized.
SummaryBiofilm production is thought to be an important step in many enterococcal infections. In several Grampositive bacteria, membrane glycolipids have been implicated in biofilm formation. We constructed a nonpolar deletion mutant of a putative glucosyltransferase designated biofilm-associated glycolipid synthesis A (bgsA) in Enterococcus faecalis 12030. Analysis of major extracted glycolipids by nuclear magnetic resonance spectroscopy revealed that the cell membrane of 12030DbgsA was devoid of diglucosyl-diacylglycerol (DGlcDAG), while monoglucosyl-diacylglycerol was overrepresented. The cell walls of 12030DbgsA contained longer lipoteichoic acid molecules and were less hydrophobic than wild-type bacteria. Inactivation of bgsA in E. faecalis 12030 and E. faecalis V583 led to an almost complete arrest of biofilm formation on plastic surfaces. Overexpression of bgsA, on the other hand, resulted in increased biofilm production. While initial adherence was not affected, bgsA-deficient bacteria did not accumulate in the growing biofilm. Also, adherence of E. faecalis DbgsA to Caco-2 cells was impaired. In a mouse bacteraemia model, E. faecalis 12030DbgsA was cleared more rapidly from the bloodstream than the wild-type strain. In summary, BgsA is a glycosyltransferase synthetizing DGlcDAG, a glycolipid and lipoteichoic acid precursor involved in biofilm accumulation, adherence to host cells, and virulence in vivo.
In a typing system based on opsonic antibodies against carbohydrate antigens of
the cell envelope, 60% of Enterococcus faecalis strains
can be assigned to one of four serotypes (CPS-A to CPS-D). The structural basis
for enterococcal serotypes, however, is still incompletely understood. Here we
demonstrate that antibodies raised against lipoteichoic acid (LTA) from a CPS-A
strain are opsonic to both CPS-A and CPS-B strains. LTA-specific antibodies also
bind to LTA of CPS-C and CPS-D strains, but fail to opsonize them. From CPS-C
and CPS-D strains resistant to opsonization by anti-LTA, we purified a novel
diheteroglycan with a repeating unit of
→6)-β-Galf-(1→3)-
β-D-Glcp-(1→ with O-acetylation in
position 5 and lactic acid substitution at position 3 of the
Galf residue. The purified diheteroglycan, but not LTA
absorbed opsonic antibodies from whole cell antiserum against E.
faecalis type 2 (a CPS-C strain) and type 5 (CPS-D). Rabbit
antiserum raised against purified diheteroglycan opsonized CPS-C and CPS-D
strains and passive protection with diheteroglycan-specific antiserum reduced
bacterial counts by 1.4 – 3.4 logs in mice infected with E.
faecalis strains of the CPS-C and CPS-D serotype.
Diheteroglycan-specific opsonic antibodies were absorbed by whole bacterial
cells of E. faecalis FA2-2 (CPS-C) but not by its isogenic
acapsular cpsI-mutant and on native PAGE purified
diheteroglycan co-migrated with the gene product of the
cps-locus, suggesting that it is synthesized by this locus. In
summary, two polysaccharide antigens, LTA and a novel diheteroglycan, are
targets of opsonic antibodies against typeable E. faecalis
strains. These cell-wall associated polymers are promising candidates for active
and passive vaccination and add to our armamentarium to fight this important
nosocomial pathogen.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.